Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · Evidence synthesis

Draft synthesis: weight change after discontinuation of an incretin receptor agonist

Consultation on the draft synthesis of weight trajectory after an incretin receptor agonist is stopped. The contributing evidence is drawn principally from the randomised withdrawal designs in STEP 4, reported in JAMA in 2021, and SURMOUNT-4, reported in JAMA…

Document identifier
CEI-CP-008
Series
Public comment period
Version
1.0
Published
05 Nov 2025
Last reviewed
05 Nov 2025
Next review
05 Nov 2026
Identifier
10.71829/cei.cp.8
Certainty
Not rated
Cycle
2025 Q3
Window
30 Jul 2025 – 28 Sep 2025
Status
Closed
Submissions
16

§1Consultation and window

§1.1Window

Opened
30 July 2025
Closed
28 September 2025
Duration
60 days
Status
Closed — the disposition is published
Document under consultation
Synthesis: Weight change after discontinuation of an incretin receptor agonist
Submissions received
16

§1.2Consultation questions

The secretariat put the following questions. A submission was not required to address them and several did not; the questions record what the Institute was uncertain about rather than restricting what a respondent could raise.

  1. Is the moderate certainty rating for the anchor outcome correctly drawn, given that the contributing designs differ in the duration of the run-in before randomised withdrawal?
  2. Is any eligible study missing from the included set, and is any included study ineligible under the registered criteria?
  3. Does the synthesis state clearly enough that a randomised withdrawal design measures the effect of stopping a drug in people who tolerated and responded to it, and not the effect of stopping it in an unselected population?

§1.3How a submission is handled

  • Every submission is signed. The Institute publishes no anonymous submission.
  • Every submission carries a declared interest. A declaration of no interest is itself a declaration and is recorded as one. A declaration is not a disqualification and the Institute has never given a submission less weight on that ground.
  • A submission from an employee of a marketing-authorisation holder is identified as an industry submission on its face, following a unanimous consultation on the conflicts policy.
  • Every submission receives a secretariat response and a disposition. Submissions that are not accepted remain published in full; the Institute does not remove a submission because it disagrees with it.
  • There is no voting, no reputation score, no reply thread and no editing after receipt.

§1.4Outcome

The synthesis was amended before ratification. The selection effect inherent in a randomised withdrawal design is now stated in the abstract, and the trajectory is reported per trial rather than pooled across trials of different run-in duration.

The disposition table, listing each submission with its disposition and the resulting amendment, is at §3.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.